The Oligonucleotide Safety Working Group (OSWG)

Nucleic Acid Therapeutics

Volumn 22, Issue 4, 2012, Pages 211-212

  Schubert, Dave ^a   Levin, Arthur A ^b   Kornbrust, Doug ^c   Berman, Cindy L ^d   Cavagnaro, Joy ^e   Henry, Scott ^f   Seguin, Rosanne ^g   Ferrari, Nicolay ^g   Shrewsbury, Stephen B ^h  

^a MediVector Inc   (United States)

^b MiRagen Therapeutics   (United States)

^c Preclinsight   (United States)

^d Independent Consultant   (United States)

^e Access BIO   (United States)

^f ISIS PHARMACEUTICALS   (United States)

^g INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^h Shrewd Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; OLIGONUCLEOTIDE;

AUTHORITY; CARCINOGENICITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HUMAN; IMMUNOMODULATION; MEDICAL SOCIETY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SCIENTIST;

CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; OLIGONUCLEOTIDES; PRACTICE GUIDELINES AS TOPIC;

EID: 84865435563     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0383     Document Type: Editorial

References (0)